Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal B vaccine + meningococcal ACWY conjugate vaccine + paracetamol
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Small Molecules
- Administration
- Intramuscular, Oral
01
Overview
This combination refers to the clinical co-administration of vaccines targeting five major serogroups of *Neisseria meningitidis* (A, B, C, W, and Y) along with paracetamol (acetaminophen). The meningococcal B vaccine (e.g., Bexsero) is a multicomponent vaccine containing recombinant proteins and outer membrane vesicles, while the meningococcal ACWY vaccine is a conjugate vaccine where capsular polysaccharides are linked to a carrier protein (such as CRM197 or tetanus toxoid). Paracetamol is administered prophylactically or therapeutically to manage the high rate of fever (pyrexia) specifically associated with the MenB vaccine, particularly in infants. This regimen is standard in several national immunization programs to provide broad protection against invasive meningococcal disease while mitigating common systemic adverse reactions.
- Other names
- MenB + MenACWY + paracetamolBexsero + Menveo + paracetamolTrumenba + Nimenrix + paracetamol
02
Targets
MenACWY (Capsular polysaccharides of Neisseria meningitidis serogroups A, C, W, and Y)fHbp (Factor H-binding protein)NadA (Neisserial adhesin A)NHBA (Neisserial heparin-binding antigen)PorAPGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal B vaccine + meningococcal ACWY conjugate vaccine + paracetamol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal B vaccine + meningococcal ACWY conjugate vaccine + paracetamol.